Ticker
BMY

Price
49.88
Stock movement down
-0.35 (-0.70%)
Company name
Bristol-Myers Squibb Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
104.69B
Ent value
161.27B
Price/Sales
2.27
Price/Book
3.36
Div yield
4.57%
Div growth
7.34%
Growth years
12
FCF payout
38.78%
Trailing P/E
16.55
Forward P/E
6.08
PEG
0.90
EPS growth
10.90%
1 year return
-38.19%
3 year return
-7.08%
5 year return
-1.38%
10 year return
-0.30%
Last updated: 2023-12-06
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
December 6, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
December 6, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.28
Dividend yield4.57%
Payout frequencyQuarterly
Maximum yield4.70%
Average yield3.24%
Minimum yield2.66%
Discount to avg yield29.09%
Upside potential41.02%
Yield as % of max yield97.19%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.57%
Current yield distribution0.63%
Yield at 100% (Min)2.66%
Yield at 90%2.85%
Yield at 80%2.93%
Yield at 50% (Median)3.17%
Yield at 20%3.52%
Yield at 10%3.69%
Yield at 0% (Max)4.70%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share2.28
Payout frequencyQuarterly
Ex-div date5 Oct 2023
EPS (TTM)2.98
EPS (1y forward)8.20
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR5.56%-3.37%
DGR TTM5.56%5.40%
DGR 3 years-0.15%4.00%
DGR 5 years7.34%5.65%
DGR 10 years2.62%7.37%
DGR 15 years2.61%5.83%
Time since last change announced364 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM73.24%38.78%
Average--
Forward27.80%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E16.55
Price to OCF8.01
Price to FCF8.76
Price to EBITDA5.63
EV to EBITDA8.68

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.27
Price to Book3.36
EV to Sales3.49
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
December 5, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
December 1, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count2.10B
EPS (TTM)2.98
FCF per share (TTM)5.63

Income statement

Loading...
Income statement data
Revenue (TTM)46.16B
Gross profit (TTM)36.02B
Operating income (TTM)9.21B
Net income (TTM)6.33B
EPS (TTM)2.98
EPS (1y forward)8.20

Margins

Loading...
Margins data
Gross margin (TTM)78.04%
Operating margin (TTM)19.96%
Profit margin (TTM)13.71%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash9.12B
Net receivables9.89B
Total current assets27.27B
Goodwill21.15B
Intangible assets35.86B
Property, plant and equipment0.00
Total assets96.82B
Accounts payable3.04B
Short/Current long term debt39.32B
Total current liabilities21.89B
Total liabilities65.70B
Shareholder's equity31.12B
Net tangible assets-25.95B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)13.07B
Capital expenditures (TTM)1.12B
Free cash flow (TTM)11.95B
Dividends paid (TTM)4.63B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity20.33%
Return on Assets6.53%
Return on Invested Capital8.98%
Cash Return on Invested Capital16.96%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open50.32
Daily high50.43
Daily low49.77
Daily Volume12.1M
All-time high81.13
1y analyst estimate81.09
Beta0.45
EPS (TTM)2.98
Dividend per share2.28
Ex-div date5 Oct 2023
Next earnings date2 Feb 2024

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-38.52%-4.80%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-33.94%-11.47%
Avg time to new high41 days13 days
Max time to new high4176 days1805 days
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 28, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 28, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
104.69B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees
34300
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Bristol-Myers Squibb's stock is down 40% despite a market increase of 20%. Read here why we think BMY may be undervalued.
November 28, 2023

iO Charts is a Seeking Alpha partner

Bristol-Myers Squibb (BMY) faces risk from patent expirations of key drugs, raising concerns about revenue shortfall and market competition. Read here for more.
November 23, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Bristol Myers' Q3 results indicate a more challenging recovery than previously communicated, leading to a downgrade in its medium-term outlook. Read more about BMY stock here.
November 22, 2023
Learn about the challenges facing Bristol-Myers Squibb as it deals with loss of exclusivity, growth concerns, and other issues. Click here for more on BMY stock.
November 21, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 21, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 20, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 20, 2023
Bristol Myers Squibb is facing short-term pressure on financial results due to generic growth impacting its flagship drug Revlimid. Read more about BMY stock here.
November 17, 2023
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) 2023 Jefferies London Healthcare Conference November 16, 2023 4:30 AM ETCompany ParticipantsTimothy Power - VP...
November 16, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 15, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
November 15, 2023
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) 2023 UBS BioPharma Conference Transcript November 8, 2023 8:00 AM ETExecutivesLynelle Hoch - Head, Cell...
November 12, 2023
iO Charts is a Seeking Alpha partnerNext page